Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Braxia Scientific Corp. functions as a medical research entity that also runs clinics, offering ketamine therapies to individuals suffering from depression and linked conditions. Beyond its clinical services, the company is actively engaged in discovering and bringing to market novel pharmaceutical compounds and innovative delivery methods. Leveraging its intellectual property development platform, Braxia Scientific innovates by developing derivatives of ketamine and psilocybin, in addition to other psychedelic substances. The organization further owns and operates several multidisciplinary clinics focused on treating a broad spectrum of mental health disorders. Braxia Scientific Corp.'s main office is located in Mississauga, Ontario.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.